Vanda Pharmaceuticals Inc.
VNDA
$6.42
$0.152.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -64.67% | -2,774.33% | -324.23% | -502.19% | -611.38% |
| Total Depreciation and Amortization | 24.72% | 61.07% | 4.37% | 2.54% | 27.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 159.27% | 8,245.76% | -87.43% | -2,391.49% | -281.73% |
| Change in Net Operating Assets | -311.96% | 321.45% | 15.71% | 432.15% | -127.43% |
| Cash from Operations | -51.50% | -1,518.99% | -116.90% | -120.15% | -537.93% |
| Capital Expenditure | 49.31% | 52.34% | 0.00% | 81.68% | 83.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -53.87% | 968.89% | 76.16% | -9.84% | 385.94% |
| Cash from Investing | -53.91% | 1,023.62% | 77.18% | -0.05% | 340.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -89.73% | -312.90% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 41.39% | -312.90% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -216.33% | 109.90% | -364.71% | 993.33% | 450.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -425.07% | 715.23% | -346.29% | -38.77% | 188.91% |